Study Identifies by Disease Marker Those Scleroderma Patients Best, and Least, Suited to Take Part in Clinical Trials
In a recent study, researchers identified advanced skin fibrosis at baseline as a predictor of likely regression — or disease improvement — in patients under standard of care measures in clinical trials, making this group the least ideal for inclusion in such trials. The study, “Prediction of improvement in skin fibrosis in diffuse cutaneous systemic…